Last reviewed 2026-04-23 · How we verify

ARV-1801

ARV-1801 is a bispecific antibody that simultaneously engages T cells and tumor cells to redirect immune attack against cancer.

ARV-1801 is a bispecific antibody that simultaneously engages T cells and tumor cells to redirect immune attack against cancer. Used for Hematologic malignancies (Phase 2 development).

At a glance

Mechanism of action

ARV-1801 functions as a bispecific T-cell engager (BiTE) that binds to CD3 on T cells and a tumor-associated antigen on cancer cells, bringing them into close proximity to facilitate T-cell activation and cytotoxic killing. This mechanism bypasses the need for traditional TCR recognition and MHC presentation, allowing direct T-cell mediated destruction of target tumor cells. The bispecific format enables potent anti-tumor activity while potentially reducing systemic toxicity compared to other immunotherapies.

Approved indications

• Hematologic malignancies (Phase 2 development)

Common side effects

• Cytokine release syndrome
• Immune effector cell-associated neurotoxicity syndrome (ICANS)
• Infections

Key clinical trials

• Oral ARV-1801 Given in Combination With Intravenous Ceftazidime or Meropenem for Treatment of Melioidosis in Hospitalized Patients (PHASE2)
• Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• ARV-1801 CI brief — competitive landscape report
• ARV-1801 updates RSS · CI watch RSS
• Arrevus Inc. portfolio CI